FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361887675> ?p ?o ?g. }

• W4361887675 abstract "<p>Figure S1. Efficacy of pemetrexed in Lewis Lung carcinoma model and metabolomic analysis of MC38 tumor bearing mice treated with 50 mg/kg of pemetrexed Figure S2. T cell inflamed phenotype induced by pemetrexed is modestly reduced in tumors upon combination with cisplatin Figure S3. Combination Effects of pemetrexed -/+ anti-PD-L1 in MC38, LLC and Colon26 tumor models Figure S4 (A) Mice bearing Colon26 tumors were treated starting 10 days after tumor implantation with pemetrexed (50 mg/kg, 5 days on, 2 days off, IP) and/or anti-PD-L1 (αPD-L1) (500 ug/mouse, weekly IP), and tumors were isolated after 14 days of treatment and single cell suspensions were subjected to flow cytometry analysis. FACS plots show representative data of intra-tumor CD45+ tumor-infiltrating lymphocyte (TIL) T cell (CD3+) and Myeloid cell (CD11b+) subsets frequencies; and percentage of Ki67+ CD4+ T effector cells based on the gating scheme indicated. (B) Spleens, TDLNs and tumors were isolated and antigen specific T cell responses were measured by IFNγ ELISpot, gp70 Tetramer staining (Tet) and Intracellular cytokine staining. (Left) CD8 T cells isolated from pooled spleens and TDLNs from individual mice were cultured alone (control) with irrelevant BALB/c tumor EMT6 or cognate Colon26 tumor cells overnight and number of IFNγ producing T cells was measured by ELISpot. (Middle) Freshly isolated CD8+ T cells from spleens and TDLNs were assessed for % of gp70 Tet+ cells. (Right) Freshly isolated tumors single cell suspensions were stimulated with PMA/ phorbol myristate acetate (PMA) and ionomycin with monensin for 4 hrs and the % of TNF-alpha positive and gp70 Tet+ CD8 T cells were measured from the Live CD45+, CD3+ T cells by FACS. Figure S5. Concordance between QuantiGene and nCounter gene expression data for in vitro activated T cells treated in the presence or absence of pemetrexed (related to Figure 6F). Supplementary Table 1. Ingenuity pathway analysis (IPA) of MC38 tumors treated with pemetrexed or paclitaxel with or without carboplatin Supplementary Table 2: IPA results for Colon26 experiment in Figure 4 sorted by functional class. Pemetrexed monotherapy in this experiment at this timepoint did not have enough differentially expressed genes to generate IPA results.</p>" @default.
• W4361887675 created "2023-04-05" @default.
• W4361887675 creator A5000205895 @default.
• W4361887675 creator A5001183616 @default.
• W4361887675 creator A5004627125 @default.
• W4361887675 creator A5011483505 @default.
• W4361887675 creator A5017582579 @default.
• W4361887675 creator A5022346083 @default.
• W4361887675 creator A5022743245 @default.
• W4361887675 creator A5024689827 @default.
• W4361887675 creator A5031401366 @default.
• W4361887675 creator A5037746795 @default.
• W4361887675 creator A5041068728 @default.
• W4361887675 creator A5046226560 @default.
• W4361887675 creator A5053568428 @default.
• W4361887675 creator A5056382986 @default.
• W4361887675 creator A5056444600 @default.
• W4361887675 creator A5063117066 @default.
• W4361887675 creator A5069290077 @default.
• W4361887675 creator A5071061160 @default.
• W4361887675 creator A5072207595 @default.
• W4361887675 creator A5072905780 @default.
• W4361887675 creator A5073967606 @default.
• W4361887675 creator A5077286863 @default.
• W4361887675 creator A5080769460 @default.
• W4361887675 creator A5082277382 @default.
• W4361887675 creator A5084679761 @default.
• W4361887675 creator A5084905250 @default.
• W4361887675 creator A5088923881 @default.
• W4361887675 date "2023-03-31" @default.
• W4361887675 modified "2023-09-26" @default.
• W4361887675 title "Supplementary Data from The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy" @default.
• W4361887675 doi "https://doi.org/10.1158/1078-0432.22471421" @default.
• W4361887675 hasPublicationYear "2023" @default.
• W4361887675 type Work @default.
• W4361887675 citedByCount "0" @default.
• W4361887675 crossrefType "posted-content" @default.
• W4361887675 hasAuthorship W4361887675A5000205895 @default.
• W4361887675 hasAuthorship W4361887675A5001183616 @default.
• W4361887675 hasAuthorship W4361887675A5004627125 @default.
• W4361887675 hasAuthorship W4361887675A5011483505 @default.
• W4361887675 hasAuthorship W4361887675A5017582579 @default.
• W4361887675 hasAuthorship W4361887675A5022346083 @default.
• W4361887675 hasAuthorship W4361887675A5022743245 @default.
• W4361887675 hasAuthorship W4361887675A5024689827 @default.
• W4361887675 hasAuthorship W4361887675A5031401366 @default.
• W4361887675 hasAuthorship W4361887675A5037746795 @default.
• W4361887675 hasAuthorship W4361887675A5041068728 @default.
• W4361887675 hasAuthorship W4361887675A5046226560 @default.
• W4361887675 hasAuthorship W4361887675A5053568428 @default.
• W4361887675 hasAuthorship W4361887675A5056382986 @default.
• W4361887675 hasAuthorship W4361887675A5056444600 @default.
• W4361887675 hasAuthorship W4361887675A5063117066 @default.
• W4361887675 hasAuthorship W4361887675A5069290077 @default.
• W4361887675 hasAuthorship W4361887675A5071061160 @default.
• W4361887675 hasAuthorship W4361887675A5072207595 @default.
• W4361887675 hasAuthorship W4361887675A5072905780 @default.
• W4361887675 hasAuthorship W4361887675A5073967606 @default.
• W4361887675 hasAuthorship W4361887675A5077286863 @default.
• W4361887675 hasAuthorship W4361887675A5080769460 @default.
• W4361887675 hasAuthorship W4361887675A5082277382 @default.
• W4361887675 hasAuthorship W4361887675A5084679761 @default.
• W4361887675 hasAuthorship W4361887675A5084905250 @default.
• W4361887675 hasAuthorship W4361887675A5088923881 @default.
• W4361887675 hasBestOaLocation W43618876751 @default.
• W4361887675 hasConcept C126322002 @default.
• W4361887675 hasConcept C147483822 @default.
• W4361887675 hasConcept C153911025 @default.
• W4361887675 hasConcept C167672396 @default.
• W4361887675 hasConcept C185592680 @default.
• W4361887675 hasConcept C203014093 @default.
• W4361887675 hasConcept C2776090121 @default.
• W4361887675 hasConcept C2776694085 @default.
• W4361887675 hasConcept C2777240266 @default.
• W4361887675 hasConcept C2778239845 @default.
• W4361887675 hasConcept C2779053233 @default.
• W4361887675 hasConcept C502942594 @default.
• W4361887675 hasConcept C71924100 @default.
• W4361887675 hasConcept C86803240 @default.
• W4361887675 hasConcept C8891405 @default.
• W4361887675 hasConceptScore W4361887675C126322002 @default.
• W4361887675 hasConceptScore W4361887675C147483822 @default.
• W4361887675 hasConceptScore W4361887675C153911025 @default.
• W4361887675 hasConceptScore W4361887675C167672396 @default.
• W4361887675 hasConceptScore W4361887675C185592680 @default.
• W4361887675 hasConceptScore W4361887675C203014093 @default.
• W4361887675 hasConceptScore W4361887675C2776090121 @default.
• W4361887675 hasConceptScore W4361887675C2776694085 @default.
• W4361887675 hasConceptScore W4361887675C2777240266 @default.
• W4361887675 hasConceptScore W4361887675C2778239845 @default.
• W4361887675 hasConceptScore W4361887675C2779053233 @default.
• W4361887675 hasConceptScore W4361887675C502942594 @default.
• W4361887675 hasConceptScore W4361887675C71924100 @default.
• W4361887675 hasConceptScore W4361887675C86803240 @default.
• W4361887675 hasConceptScore W4361887675C8891405 @default.
• W4361887675 hasLocation W43618876751 @default.
• W4361887675 hasLocation W43618876752 @default.
• W4361887675 hasOpenAccess W4361887675 @default.
• W4361887675 hasPrimaryLocation W43618876751 @default.
• W4361887675 hasRelatedWork W1967647128 @default.

• next